Sollis Therapeutics Stock

sollistx.comHealthcareFounded: 2017Funding to Date: $49.89MM

Sollis Therapeutics is a clinical-stage pharmaceutical company developing novel interventional non-steroid, non-opioid analgesics.

Register for Details

For more details on financing and valuation for Sollis Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to the Forge Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Sollis Therapeutics.

Register Today

Team

Management Team

Gregory Fiore MD
Co-Founder, Chief Executive Officer, President and Board Member
Bryan Jones JD
Chief Operating Officer & Co-Founder

Board Members

Greg Licholai MD
Richard Mott
Andrew ElBardissi MD
Deerfield Management
Kevin Wasserstein
Neurotechnology Innovations Translator
Gregory Fiore MD
Steven Hochberg

Other companies like Sollis Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$3.6B
Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$4.8B
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$296.3MM